Protagenic Therapeutics, Incnew Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Garo H Armen, EXEC. CHAIR & PRINCIPAL OFF and a Director of Protagenic Therapeutics, Inc.new, purchased 2,220 shares of common stock on August 11, 2026 for $0.32 per share.
OQB
Garo H Armen, EXEC. CHAIR & PRINCIPAL OFF and a Director of Protagenic Therapeutics, Inc.new, purchased 685 shares of common stock on August 6, 2026 for $0.22 per share.
OQB
Garo H Armen, EXEC. CHAIR & PRINCIPAL OFF and a Director of Protagenic Therapeutics, Inc.new, purchased 5,000 shares of common stock on August 5, 2026 for $0.26 per share.
OQB
Garo H Armen, EXEC. CHAIR & PRINCIPAL OFF. and a Director of Protagenic Therapeutics, Inc.new, purchased 26,291 shares of common stock on July 30, 2026 for $0.18 per share.
OQB
Director Timothy R. Wright acquired options for 21,250 shares of Protagenic Therapeutics (PTIX) common stock on March 25, 2024.
OQB
Robert Benjamin Stein, a director of Protagenic Therapeutics, acquired options for 75,000 shares of PTIX common stock on March 25, 2024.
OQB
Director Khalil Barrage acquired 22,500 options in Protagenic Therapeutics (PTIX) on March 25, 2024, at an exercise price of $1.74.
OQB
Jennifer Buell, a director at Protagenic Therapeutics, acquired options to purchase 75,000 shares of PTIX common stock on March 25, 2024.
OQB
Garo H. Armen, Executive Chairman of Protagenic Therapeutics, acquired 250,000 stock options on March 25, 2024, according to a Form 4 filing.
OQB
Director Brian Corvese acquired options for 43,750 shares of Protagenic Therapeutics (PTIX) common stock at an exercise price of $1.74 on March 25, 2024.
OQB
Alexander K. Arrow, Chief Financial Officer of Protagenic Therapeutics, acquired options to purchase 100,000 shares of the company's common stock on March 25, 2024.